![The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/ae45e197-ac92-433e-b3c4-5599fd600d0b/gr1_lrg.gif)
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet
![Adverse events with zonisamide according to duration of treatment (n=60) | Download Scientific Diagram Adverse events with zonisamide according to duration of treatment (n=60) | Download Scientific Diagram](https://www.researchgate.net/publication/26279462/figure/tbl2/AS:202590022311945@1425312633443/Adverse-events-with-zonisamide-according-to-duration-of-treatment-n60.png)
Adverse events with zonisamide according to duration of treatment (n=60) | Download Scientific Diagram
![Reflections on the Use of Perampanel in Epilepsy – Lessons from the Clinic and Real-world Evidence - touchNEUROLOGY Reflections on the Use of Perampanel in Epilepsy – Lessons from the Clinic and Real-world Evidence - touchNEUROLOGY](https://www.touchneurology.com/wp-content/uploads/sites/3/2017/05/Figure_1__Adverse_events_reported.png)
Reflections on the Use of Perampanel in Epilepsy – Lessons from the Clinic and Real-world Evidence - touchNEUROLOGY
![Analytica | Free Full-Text | Ion-Channel Antiepileptic Drugs: An Analytical Perspective on the Therapeutic Drug Monitoring (TDM) of Ezogabine, Lacosamide, and Zonisamide Analytica | Free Full-Text | Ion-Channel Antiepileptic Drugs: An Analytical Perspective on the Therapeutic Drug Monitoring (TDM) of Ezogabine, Lacosamide, and Zonisamide](https://pub.mdpi-res.com/analytica/analytica-02-00016/article_deploy/html/images/analytica-02-00016-ag.png?1638910033)